Introduction
The purification of influenza virus vaccine has been facilitated by two major technological advances, namely the development of zonal rotors capable of processing large volumes ot fluid, and the application of surfactants, lipid solvents or proteases to disrupt the influenza virion. However, application of either of these two principles can still leave one with a vaccine which contains large amounts of matrix and nuclear proteins, which do not appear to contribute to the protective efficacy of the vaccine and are probably responsible for at least some of the local and systemic reactions occurring in vaccinated subjects.
In general, however, disruption of the virus particle is accompanied by a loss of antigenicity. The more efficient the breakdown and the more stringent the purification of selected protein fractions, the greater tends to be the overall loss of antigenicity. The surface proteins, the haemagglutinin and neuraminidase, are of relatively low molecular weight and apart from actual process losses of antigenic mass, the separated antigens appear to have less potential than does the same amount of material in the intact particle. This problem can be readily overcome by the incorporation of a mineral carrier such as aluminium hydroxide.
A vaccine consisting of haemagglutinin and neuraminidase antigens adsorbed on to aluminium hydroxide gel ('Alhydrogel') was prepared and the dose response to 0 5 ml doses containing different amounts of antigen was studied in volunteers. Purified virus diluted to 10 1 as described above was allowed to flow across this gradient and disruption occurred as the virus particles sedimented through the band of Triton. The rotor was operated for a further hour at room temperature and 90,000 g to separate the split products, the surface antigens sedimenting in the Triton layer, while the core and matrix proteins settled in the denser poition of the gradient.
Materials and methods

Virus
Removal of Triton
The fractions from the gradient which contained surface proteins were pooled and phosphate buffer (2 mol/l pH 7T0) was added to give a final concentration of 0 5 mol/l. Under these conditions, the cloudpoint of the surfactant was exceeded at room temperature. The solution was allowed to stand at room temperature overnight and the Triton separated as a narrow upper layer, which also contained phospholipids. The lower phase containing the surface proteins of the virus was removed.
Adsorption ofsurface antigens to aluminium hydroxide Alhydrogel (Superphos Ltd) (2%. w/v Al(OH)3 in water) was added to the concentrated surface antigens after removal of Triton. The suspension was allowed to stand overnight at 4°C and then diluted to the required strength. Vaccines were prepared containing 400 i.u./0 5 ml, 200 i.u./0 5 ml, 100 i.u./0 5 ml, 50 i.u./0 5 ml and 25 i.u./0 5 ml. The final vaccine contained AI(OH)3 (5 mg/mI) in 0-1 mol/l phosphate buffer.
Standardization of vaccine
The haemagglutinin content of the vaccine was standardized by radial diffusion (Schild, HenryAymard and Pereira, 1972) using antiserum prepared in rabbits to bromelain-derived haemagglutinin (Brand and Skehel, 1972) . Neuraminidase was estimated by direct assay of enzyme activity in an autoanalyser (Bevan, Furminger and Smith, 1975) .
Electron microscopy Dilute samples were concentrated by sedimentation and resuspended in PBS. Samples were added to carbon-coated formvar grids and salts were removed by addition and removal of distilled water to the grid. Phosphotungstic acid (2.500 w/v) pH 6-8 was used as a negative stain.
Results Figure 1 shows the distribution of viral components after virus particles have been centrifuged through a sucrose gradient containing Triton NIOI. The protein peak at the dense end of the gradient represents the stripped particles or cores and some residual unsplit virus as indicated by the small neuraminidase peak. The protein at the top of the gradient consists of haemagglutinin and neuraminidase close to the surfactant band. Figure 2 shows the effect of removing surfactant from a pool of the fractions containing haemagglutinin and neuraminidase. The two surface proteins form separate aggregates and the stellate groups of haemagglutinin particles contrast strongly with the cartwheel formations of neuraminidase. No particles of core protein were observed and specific testing with core protein antibody by radial diffusion gave a negative reaction (Oxford, 1974) .
Serological studies
For studies in volunteers, serial two-fold dilutions of material prepared from the A/Port Chalmers/1/73 strain were made in aluminium hydroxide gel so that the concentration of gel was constant at 2-5 mg per dose (= 0-86 mg aluminium) at each dose level. Subjects with no recent history of influenza-like illness and who had not received influenza vaccine within the previous 12 months were bled and their serum HI (haemagglutination inhibition) and NI titres determined. They were then distributed into groups so that the numbers with low and high HI antibody levels were evenly matched. The diluted vaccines were coded and each group was given a different dilution on a random basis. Two to three weeks later a further blood sample was taken and antibody levels again determined.
The results are shown in the following tables, the titres being shown as reciprocal values in each case. If the subjects with low HI antibody levels are considered (Table 1) With neuraminidase antibody, on the other hand (Table 3) there is a very marked fall in response to doses below 200 units. It has been suggested that subunit vaccines produce a narrower HI response than do whole virus vaccines. This does not, however, seem to be the case with our adsorbed preparations, since the spectrum of antibody response in six subjects, all of whom had an HI titre of 1 : 12 before vaccination, was broad (as seen in Table 4 ). Table 5 shows the antibody response in elderly subjects to purified surface antigen vaccine, and although it does not appear to be as good as in young adults, it is adequate. Table 6 shows the results of a challenge study in student volunteers who received 400 i.u. of a surface antigen vaccine prepared from the A2/Eng/42/72 strain and were subsequently challenged with the attenuated MRC-7 recombinant.
As can be seen, the incidence of a successful challenge in the control group was 57°4 compared with approximately 4VO in the vaccinated subjects.
Discussion
Previous studies in ferrets (Brady and Furminger, 1975) had shown that a vaccine prepared from purified influenza haemagglutinin and neuraminidase was effective in protecting these animals against challenge infection with the homologous strain of virus. It was therefore of interest to investigate the antibody response and reactogenicity in human subjects and the response of volunteers to direct challenge with an attenuated virus.
The lack of any general reactions and the absence of any reports of severe local reactions to the surface group.bmj.com on April 11, 2017 -Published by http://pmj.bmj.com/ Downloaded from antigens suggests that the further purification involved in removing core and matrix proteins has resulted in a more satisfactory vaccine. The additional purity may also account for the flatness of the dose response curve to the haemagglutinin, by minimizing the extent of antigenic competition.
A similarly flat dose response has been observed in chickens, but the bird-to-bird variation makes this species an unsatisfactory test animal for standardization of the vaccine.
Further studies are in progress to assess the duration of the antibody response and to study the response of volunteers to challenge infections after graded doses of antigen. 
